Search
Search Results
-
[18F]FDG PET/CT Imaging in Cancer Treatment with Checkpoint Inhibitors
In the last decade, the development of new therapeutic agents modulating the activity of the immune system and boosting its response against cancer...
-
Epithelial−mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer
BackgroundWe investigated the role of tumor cell-intrinsic PD-L1 signaling in the epithelial−mesenchymal transition (EMT) in non-small-cell lung...
-
Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review
BackgroundAlthough numerous studies have reported the prognostic value of the lung immune prognostic index (LIPI) in non-small cell lung cancer...
-
Immune Checkpoint Therapy: A New Opportunity for Cancer Treatment
Due to improved understanding of the tumor biology and immunology, cancer immunotherapy has rapidly developed as a promising strategy to treat...
-
Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity
The growing success of immune checkpoint inhibitors (ICIs) has led to improved outcomes in several types of cancers with studies looking for...
-
PARP inhibitor and immune checkpoint inhibitor have synergism efficacy in gallbladder cancer
Gallbladder cancer (GBC) is an aggressive cancer with poor prognosis. PARP inhibitors (PARPi) target PARP enzymes and have shown efficacy in patients...
-
Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review
The availability of immune-checkpoint inhibitors (ICI) in the last decade has resulted in a paradigm shift in certain areas of oncology. Patients can...
-
Immune selection determines tumor antigenicity and influences response to checkpoint inhibitors
In cancer, evolutionary forces select for clones that evade the immune system. Here we analyzed >10,000 primary tumors and 356...
-
Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with liver metastases
Nearly one-fifth of patients with non-small cell Lung Cancer (NSCLC) will develop liver metastases (LMs), and the overall treatment strategy of LMs...
-
Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired
Cancer is still the leading cause of death globally. The approval of the therapeutic use of monoclonal antibodies against immune checkpoint...
-
A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review
A pharmacological class known as immune checkpoint inhibitors (ICIs) has been developed as a potential treatment option for various malignancies,...
-
Time-Dependent Pharmacokinetics of Immune Checkpoint Inhibitors and their Implications and Considerations for Exposure–Response Analysis
PurposeThe purpose of this review is to provide a comprehensive summary of recent studies characterizing the pharmacokinetics of newly approved...
-
mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers
BackgroundmTOR pathway is known to promote cancer malignancy and influence cancer immunity but is unknown for its role in immune checkpoint...
-
Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?
Sarcomas are a group of diverse and complex cancers of mesenchymal origin that remains poorly understood. Recent developments in cancer immunotherapy...
-
A Review of Neurotoxicities Associated with Immune Checkpoint Inhibitors
The last decade has seen an exponential rise in the use of immune checkpoint inhibitors (ICIs). The use of ICIs has given new hope in cancer...
-
Anti-integrin αvβ6 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitis
BackgroundNo specific biomarker for immune checkpoint inhibitor (ICI)-induced colitis has been established. Previously, we identified anti-integrin...
-
Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors
BackgroundImmune-mediated pneumonitis has a high mortality rate; however, information regarding the related risk factors remains limited. This study...
-
The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors
BackgroundImmune checkpoint inhibitors (ICI) are approved for treatment of recurrent or metastatic oropharyngeal head and neck squamous cell...
-
Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition
BackgroundImmune checkpoint inhibitors have transformed the treatment landscape of many cancers, including melanoma and renal cell carcinoma (RCC)....
-
Prediction model for hyperprogressive disease in patients with advanced solid tumors received immune-checkpoint inhibitors: a pan-cancer study
BackgroundHyper progressive disease (HPD) describes the phenomenon that patients can’t benefit from immunotherapy but cause rapid tumor progression....
